Description
Summary Information: Altraz is a medication provided in the form of oral tablets, containing the active substance Anastrozole. Each tablet typically contains 1mg of Anastrozole. Altraz is primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. Anastrozole belongs to a class of medications known as aromatase inhibitors, which work by inhibiting the enzyme aromatase, thereby reducing the production of estrogen, a hormone that promotes the growth of certain types of breast cancer cells.
Product Composition: The active pharmaceutical ingredient in Altraz tablets is Anastrozole. Anastrozole is a selective nonsteroidal aromatase inhibitor that blocks the conversion of androgens to estrogen, effectively reducing estrogen levels in the body. In addition to Anastrozole, Altraz tablets may contain various excipients and coatings to ensure proper formulation and stability.
Manufacturer: Altraz tablets are manufactured by Cytomed, a division of Alkem Laboratories Ltd. Alkem Laboratories is a multinational pharmaceutical company known for producing a wide range of high-quality generic medications and healthcare products. Cytomed, a specialized division of Alkem Laboratories, focuses on oncology and provides innovative treatment options for cancer patients.
Package: Altraz tablets are typically supplied in packs containing multiple tablets, each with a dosage strength of 1mg of Anastrozole. The packaging may include information such as the expiration date, lot number, and manufacturer details.
Usage Instructions: Altraz tablets are taken orally with water, usually once daily, or as directed by a healthcare professional. The dosage and duration of treatment may vary depending on factors such as the stage of breast cancer, hormone receptor status, and individual patient response. It is essential to follow the prescribed regimen closely and not to exceed recommended dosages without medical supervision.
Benefits:
- Breast Cancer Treatment: Altraz is effective in the treatment of hormone receptor-positive breast cancer in postmenopausal women, reducing the risk of disease recurrence and improving overall survival rates.
- Estrogen Suppression: Anastrozole inhibits the production of estrogen, a hormone that promotes the growth of certain types of breast cancer cells, thereby slowing down or halting tumor growth and progression.
- Adjuvant Therapy: Altraz may be used as adjuvant therapy following surgery or other primary treatments to reduce the risk of cancer recurrence and improve long-term outcomes for breast cancer patients.
- Well-Tolerated: Altraz is generally well-tolerated, with manageable side effects such as hot flashes, joint pain, and fatigue reported infrequently, allowing for improved treatment adherence and patient comfort.
It is important to note that Altraz should only be used under the supervision of a qualified healthcare professional experienced in the management of breast cancer. Patients should be monitored regularly for treatment response and potential side effects, and appropriate supportive care should be provided as needed throughout the course of treatment.
Reviews
There are no reviews yet.